We are live on
!
Find out more
CCM
Catalio Capital Management Portfolio holdings
AUM
$479M
1-Year Est. Return
140.7%
This Fund
S&P 500
This Quarter
Est. Return
+10.31%
1 Year Est. Return
+140.7%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$457M
AUM Growth
–
Cap. Flow
+$474M
Cap. Flow
% of AUM
103.79%
Top 10 Holdings %
Top 10 Hldgs %
57.34%
Holding
33
New
33
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$34.3M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$28.3M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$27.9M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$26.7M |
| 5 |
LivaNova
LIVN
|
+$26.3M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Becton Dickinson
BDX
$43.1B
| $33.7M | 7.38% |
+148,615
| New | +$34.3M |
|
|
2
Ascendis Pharma A/S
ASND
$16.7B
| $29.7M | 6.49% |
+215,587
| New | +$28.3M |
|
|
3
Bristol-Myers Squibb
BMY
$127B
| $28.2M | 6.18% |
+499,151
| New | +$27.9M |
|
|
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
| $27.6M | 6.04% |
+764,668
| New | +$26.7M |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $24.8M | 5.43% |
+284,654
| New | +$26.1M |
|
6
Edwards Lifesciences
EW
$47.6B
| $24.7M | 5.4% |
+333,144
| New | +$23.3M |
|
7
BridgeBio Pharma
BBIO
$16.5B
| $24.7M | 5.39% |
+898,458
| New | +$23.2M |
|
|
8
LivaNova
LIVN
$4.3B
| $23.7M | 5.19% |
+512,447
| New | +$26.3M |
|
|
SEPN
9
Septerna Inc
SEPN
$1.49B
| $23.5M | 5.13% |
+1,024,245
| New | +$24.2M |
|
10
Cytokinetics
CYTK
$11B
| $21.5M | 4.71% |
+457,587
| New | +$23.8M |
|
11
Envista
NVST
$4.28B
| $19.7M | 4.3% |
+1,019,529
| New | +$20.2M |
|
12
Veracyte
VCYT
$4.52B
| $19.4M | 4.25% |
+490,547
| New | +$18.6M |
|
13
Intuitive Surgical
ISRG
$121B
| $19.3M | 4.21% |
+36,910
| New | +$19.2M |
|
|
EXAS
14
DELISTED
Exact Sciences
EXAS
| $17.4M | 3.8% |
+309,103
| New | +$19.2M |
|
15
Dianthus Therapeutics
DNTH
$5.68B
| $16.6M | 3.64% |
+763,471
| New | +$19.6M |
|
16
uniQure
QURE
$2.68B
| $15.9M | 3.48% |
+901,973
| New | +$7.79M |
|
17
Structure Therapeutics
GPCR
$3.49B
| $15.4M | 3.38% |
+569,395
| New | +$20.2M |
|
|
MASI
18
DELISTED
Masimo
MASI
| $14.4M | 3.16% |
+87,377
| New | +$13.8M |
|
19
Disc Medicine
IRON
$2.83B
| $11.4M | 2.49% |
+179,815
| New | +$10.4M |
|
20
ADMA Biologics
ADMA
$1.92B
| $8.79M | 1.92% |
+512,724
| New | +$9.65M |
|
|
NARI
21
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $6.77M | 1.48% |
+132,545
| New | +$6.51M |
|
22
Boston Scientific
BSX
$65.8B
| $6.51M | 1.42% |
+72,925
| New | +$6.42M |
|
23
Keros Therapeutics
KROS
$199M
| $6.45M | 1.41% |
+407,292
| New | +$21.2M |
|
24
Protara Therapeutics
TARA
$226M
| $5.75M | 1.26% |
+1,088,691
| New | +$3.52M |
|
|
MRSN
25
DELISTED
Mersana Therapeutics
MRSN
| $2.44M | 0.53% |
+68,201
| New | +$3.53M |
|
Similar funds
FFG
RFWA
SWM
CMI
TCM
LIM
MVP
YLHM
Catalio Capital Management's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for Catalio Capital Management, which disclosed 33 positions worth $457M. Its ten largest holdings account for 57% of the portfolio.
Its largest position is Becton Dickinson: 148,615 shares worth $33.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Catalio Capital Management's largest Q4 2024 buy was Becton Dickinson: 148,615 shares worth $33.7M.
- Catalio Capital Management's ten largest holdings make up 57% of its $457M portfolio in Q4 2024.
- Catalio Capital Management disclosed 33 positions in Q4 2024, its first 13F filing on record.
Based on Catalio Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.